Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study

Journal of Experimental & Clinical Cancer Research

Shin-ei Kudo¹  Hiroyuki Kida¹  Yusuke Takehara¹  Shumpei Mukai¹  Michitaka Suzuki¹  Hitoshi Satodate¹  Noriko Odaka¹  Haruhiro Inoue¹  Hiroaki Ito¹ 

[1] Digestive Disease Center, Showa University Northern Yokohama Hospital, 35-1 Chigasakichuo Tsuzuki-ku, Yokohama, 224-8503, Japan

关键词: Lymph node metastasis;    Gastric cancer;    Esophageal cancer;    Esophagogastric junctional cancer;   

Others  :  825511
DOI  :  10.1186/1756-9966-32-2

 received in 2012-12-09, accepted in 2013-01-04,  发布年份 2013

【 摘 要 】

Background

Esophagogastric junctional (EGJ) cancer occurs in the mucosa near the esophagogastric junction, and has characteristics of both esophageal and gastric malignancies; its optimal treatment strategy is controversial.

Methods

We conducted a single-center retrospective cohort study of the patients who underwent curative surgery with lymphadenectomy for EGJ cancer. Tumor specimens were categorized by histology and location into four types—centered in the esophagus < 5 cm from EGJ (type E), which were subtyped as (i) squamous-cell carcinoma (SQ) or (ii) adenocarcinoma (AD); (iii) any histological tumor centered in the stomach < 5 cm from EGJ, with EGJ invasion (type Ge); (iv) any histological tumor centered in the stomach < 5 cm from EGJ, without EGJ invasion (type G)—and classified by TNM system; these were compared to patients’ clinicopathological characteristics and survival outcomes.

Results

A total of 92 EGJ cancer patients were studied. Median follow-up of surviving patients was 35.5 months. Tumors were categorized as 12 type E (SQ), 6 type E (AD), 27 type Ge and 47 type G; of these 7 (58.3%), 3 (50%), 19 (70.4%) and 14 (29.8%) and 23 patients, respectively, had lymph node metastases. No patients with type E (AD) and Ge tumors had cervical lymph node metastasis; those with type G tumors had no nodal metastasis at cervical and mediastinal lymph nodes. Multivariate analysis showed that type E (AD) tumor was an independent prognostic factor.

Conclusions

We should distinguish type Ge tumor from type E (AD) tumor because of the clinicopathological and prognostic differentiation. Extended gastrectomy with or without lower esophagectomy according to tumor location and lower mediastinal and abdominal lymphadenectomy are recommended for EGJ cancer.

Trial registration

University Hospital Medical Information Network in Japan, UMIN000008596.

【 授权许可】

   
2013 Ito et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Health Organization. International Agency for Research on Cancer: GLOBOCAN 2008. Cancer Incidence and Mortality World Wide. 2008. [http://globocan.iarc.fr/ webcite]
• [2]Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Nat Cancer Inst 2005, 97:142-146.
• [3]Lu YK, Li YM, Gu YZ: Cancer of esophagus and esophagogastric junction: analysis of results of 1,025 resections after 5 to 20 years. Ann Thoracic Surg 1987, 43:176-181.
• [4]Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005, 90:139-146.
• [5]Siewert JR, Stein HJ, Feith M: Adenocarcinoma of the esophago-gastric junction. Scand J Surg 2006, 95:260-269.
• [6]Edge SB, Byrd DR, Compton CC (Eds): AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2009.
• [7]Sobin LH, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Oxford: Wiley-Blackwell; 2010.
• [8]Berger B, Stahlberg K, Lemminger A, Bleif M, Belka C, Bamberg M: Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer. Oncol 2011, 81:387-394.
• [9]Stahl M: Is there any role for surgery in the multidisciplinary treatment of esophageal cancer? Ann Oncol 2010, 21:283-285.
• [10]Nakajima T, Nishi M, Kajitani T: Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9,700 cases in the Cancer Institute Hospital. Tokyo. Sem Surg Oncol 1991, 7:365-372.
• [11]Peeters KC, van de Velde CJ: Improving treatment outcome for gastric cancer: the role of surgery and adjuvant therapy. J Clinical Oncol 2003, 21:272-273.
• [12]Diazde Liano A, Yarnoz C, Artieda C, Aguilar R, Viana S, Artajona A, Ortiz H: Results of R0 surgery with D2 lymphadenectomy for the treatment of localised gastric cancer. Clin Translat Oncol 2009, 11:178-182.
• [13]Siewert JR, Stein HJ, Sendler A, Fink U: Surgical resection for cancer of the cardia. Sem Surg Oncol 1999, 17:125-131.
• [14]Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. British J Surg 1998, 85:1457-1459.
• [15]Japan Esophageal Society: Japanese Classification of Esophageal Cancer. 10th edition: part I. Esophagus 2009, 6:1-25.
• [16]Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O: Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg 2009, 33:95-103.
• [17]Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010, 182:93-106.
• [18]Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M: Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006, 7(8):644-651.
• [19]Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, Morita M, Sakaguchi Y, Toh Y, Maehara Y: Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today 2012, 42:351-358.
• [20]Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol 2009, 16:304-310.
• [21]Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004, 22:2395-2403.
• [22]Reim D, Gertler R, Novotny A, Becker K, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H, et al.: Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012, 19:2108-2118.